APG Asset Management N.V. Sells 884 Shares of Insulet Co. (NASDAQ:PODD)

APG Asset Management N.V. decreased its position in shares of Insulet Co. (NASDAQ:PODD) by 1.3% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 66,033 shares of the medical instruments supplier’s stock after selling 884 shares during the period. APG Asset Management N.V. owned approximately 0.09% of Insulet worth $12,433,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Sunbelt Securities Inc. bought a new position in Insulet during the 1st quarter valued at about $29,000. International Assets Investment Management LLC bought a new position in shares of Insulet during the second quarter valued at approximately $32,000. UMB Bank n.a. raised its holdings in shares of Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 81 shares during the period. Jones Financial Companies Lllp bought a new stake in shares of Insulet during the 4th quarter worth approximately $40,000. Finally, CVA Family Office LLC boosted its holdings in Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares during the period.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. BTIG Research reduced their target price on Insulet from $270.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Piper Sandler lifted their price objective on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Barclays upped their target price on shares of Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. UBS Group lifted their price target on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Finally, Canaccord Genuity Group increased their price objective on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $231.71.

Insulet Stock Performance

Shares of Insulet stock opened at $232.03 on Friday. Insulet Co. has a one year low of $125.82 and a one year high of $243.98. The company has a 50-day simple moving average of $206.81 and a two-hundred day simple moving average of $190.42. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. The company has a market capitalization of $16.27 billion, a PE ratio of 70.31, a P/E/G ratio of 4.47 and a beta of 1.21.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The business had revenue of $488.50 million for the quarter, compared to analysts’ expectations of $488.00 million. During the same quarter in the prior year, the company posted $0.38 EPS. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. Research analysts expect that Insulet Co. will post 3.04 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.